

PERSONAL INFORMATION **MONICA NIGER**

Fondazione IRCCS
Istituto Nazionale dei Tumori
Prof. Filippo de Braud
Direttore SC Medicina Oncologica 1

Sex F | Date of birth 07 Jun 1987 | Nationality Italian

WORK EXPERIENCE

As part of the **SPECIALISATION SCHOOL IN MEDICAL ONCOLOGY:**

JAN 2017 – TODAY **YALE SCHOOL OF MEDICINE, DEPARTMENT OF THERAPEUTIC RADIOLOGY**
Laboratory associate. Involved in a project regarding novel mechanisms of DNA repair inhibitors sensitivity in solid tumors. Collaborator in clinical trial and grant writing.
MENTORS: Dr. R. Bindra; Dr. P. LoRusso

JAN 2017 – TODAY **YALE SCHOOL OF MEDICINE, DEPARTMENT OF MEDICAL ONCOLOGY**
Observer at Phase I Clinic.
MENTOR: Dr P. LoRusso; Dr. P. Eder

JAN 2013 – DEC 2016 **IRCCS ISTITUTO NAZIONALE DEI TUMORI, MILANO, ITALY, DEPARTMENT OF MEDICAL ONCOLOGY**
Fellow. Clinical training in Medical Oncology, focused mostly on GI tract cancer and Phase I trials.
MENTOR: Prof. F. de Braud

JUL 2012 – DEC 2012 **IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO, ITALY, CARDIOLOGY DEPARTMENT**
Fellow. Clinical training.
MENTOR: Dr F. Massari

EDUCATION AND TRAINING

12 JUL 2017 **GRADUATION AS MEDICAL ONCOLOGIST**
UNIVERSITY OF MILANO
THESIS: "EXPLOITING ONCOMETABOLITE-INDUCED BRCAness: FROM BENCH TO BEDSIDE."
TUTORS: Prof F. de Braud, Dr. R. Bindra
FINAL GRADE: 70/70 cum laude

JUL 2012 – JUL 2017 **SPECIALISATION SCHOOL IN MEDICAL ONCOLOGY**
UNIVERSITY OF MILANO

OCT 2005 – OCT 2011 **MEDICAL DEGREE, UNIVERSITY OF MILANO, ITALY.**
THESIS: "Rad 001 (everolimus) as a second line therapy in biliary tract cancer: a phase II trial"
TUTORS: Prof A. M. Gianni, Dr. R. Buzzoni
FINAL GRADE: 110/110

24 months of clinical training at Medical Oncology Department, IRCCS Fondazione

PERSONAL SKILLS

- Mother tongue Italian
- Other language English, fluent
- First Certificate in English (FCE), 2004
- Computer skills
- Good command of office suite (word processor, spread sheet, presentation software)
 - Good command of photo editing software gained as an amateur photographer
- Driving licence B

ADDITIONAL INFORMATION

Memberships ASCO, AACR, ESMO, AIOM

Publications **Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer.**

Oddo D, Siravegna G, Gloghini A, Vernieri C, Mussolin B, Morano F, Crisafulli G, Berenato R, Corti G, Volpi CC, Buscarino M, Niger M, Dunne PD, Rospo G, Valtorta E, Bartolini A, Fucà G, Lamba S, Martinetti A, Di Bartolomeo M, de Braud F, Bardelli A, Pietrantonio F, Di Nicolantonio F.

Br J Cancer. 2017 Jun 27. doi: 10.1038/bjc.2017.196. [Epub ahead of print]

Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors.

Verzoni E, Grassi P, Ratta R, Niger M, De Braud F, Valdagni R, Procopio G. Ther Adv Med Oncol. 2016 Sep;8(5):323-30. doi: 10.1177/1758834016656493.

GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study.

Pietrantonio F, Berenato R, Maggi C, Caporale M, Milione M, Perrone F, Tamborini E, Baratti D, Kusamura S, Mariani L, Niger M, Mennitto A, Gloghini A, Bossi I, Settanni G, Busico A, Bagnoli PF, Di Bartolomeo M, Deraco M, de Braud F.

J Transl Med. 2016 May 6;14(1):125. doi: 10.1186/s12967-016-0877-x.

Predicting Molecular Models: Where Are We Going?

Ratta R, Verzoni E, Grassi P, Niger M, Procopio G. EBioMedicine. 2015 Oct 9;2(11):1594-5. doi: 10.1016/j.ebiom.2015.09.050.

Progress in treatments for colorectal cancer peritoneal metastases during the years 2010-2015. A systematic review.

Baratti D, Kusamura S, Pietrantonio F, Guaglio M, Niger M, Deraco M. Crit Rev Oncol Hematol. 2016 Apr;100:209-22. doi: 10.1016/j.critrevonc.2016.01.017.

BRAF in metastatic colorectal cancer: the future starts now.

Orlandi A, Ceglie A, Inno A, Berenato R, Caporale M, Niger M, Bossi I, Di Bartolomeo M, de Braud F, Pietrantonio F.

Pharmacogenomics. 2015 Dec;16(18):2069-81. doi: 10.2217/pgs.15.140.

A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer.

Pietrantonio F, Aprile G, Rimassa L, Franco P, Lonardi S, Cremolini C, Biondani P, Sbicego EL, Pasqualetti F, Tomasello G, Niger M, Casagrande M, Ghidini M, Muni R, Montrone S, Bergamo F, Berenato R, Fontanella C, Bozzarelli S, Moretto R, Battaglin F, Di Bartolomeo M, de Braud F, Miceli R.

Radiother Oncol. 2015 Nov;117(2):315-21. doi: 10.1016/j.radonc.2015.08.023.

Palonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapy.

Celio L, Niger M, Ricchini F, Agustoni F. Core Evid. 2015 Aug 21;10:75-87. doi: 10.2147/CE.S65555.

Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase.

Falvella FS, Caporale M, Cheli S, Martinetti A, Berenato R, Maggi C, Niger M, Ricchini F, Bossi I, Di Bartolomeo M, Sottotetti E, Bernardi FF, de Braud F, Clementi E, Pietrantonio F. Int J Mol Sci. 2015 Apr 21;16(4):8884-95. doi: 10.3390/ijms16048884.

Palonosetron plus dexamethasone in highly emetogenic chemotherapy: pooled data